Wedbush Research Analysts Reduce Earnings Estimates for ACRS

Key Points

• Wedbush analysts have lowered their FY2026 earnings per share estimate for Aclaris Therapeutics to ($0.53), reflecting a pessimistic outlook on the company.
• Despite the lowered EPS forecast, Wedbush maintains an "Outperform" rating with an $8.00 price target, while the consensus estimate is ($0.82) per share.
• The stock has seen mixed reviews from analysts, with one sell rating, eight buy ratings, and an average price target of $8.71 indicating a consensus rating of "Moderate Buy."

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Analysts at Wedbush reduced their FY2026 earnings per share estimates for Aclaris Therapeutics in a research report issued to clients and investors on Wednesday, July 30th. Wedbush analyst M. Fan now forecasts that the biotechnology company will post earnings of ($0.53) per share for the year, down from their prior estimate of ($0.52). Wedbush currently has a "Outperform" rating and a $8.00 target price on the stock. The consensus estimate for Aclaris Therapeutics' current full-year earnings is ($0.82) per share.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last announced its quarterly earnings results on Tuesday, May 6th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 732.42% and a negative return on equity of 30.73%.

Other equities research analysts have also issued reports about the stock. Piper Sandler assumed coverage on shares of Aclaris Therapeutics in a report on Thursday, July 10th. They issued an "overweight" rating and a $6.00 target price on the stock. Scotiabank lowered their price target on Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating on the stock in a research report on Friday, May 9th. Finally, HC Wainwright reissued a "buy" rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research report on Wednesday, June 25th. One research analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $8.71.

Aclaris Therapeutics Price Performance

Aclaris Therapeutics stock remained flat at $1.53 during trading hours on Friday. 1,094,014 shares of the company's stock traded hands, compared to its average volume of 1,329,236. Aclaris Therapeutics has a 1 year low of $1.05 and a 1 year high of $5.17. The stock has a market capitalization of $165.67 million, a PE ratio of -1.10 and a beta of 0.30. The stock has a 50 day moving average of $1.51 and a 200-day moving average of $1.65.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ACRS. Adage Capital Partners GP L.L.C. purchased a new position in shares of Aclaris Therapeutics during the 4th quarter valued at about $23,876,000. Vivo Capital LLC purchased a new position in shares of Aclaris Therapeutics during the 4th quarter worth approximately $22,044,000. Rock Springs Capital Management LP lifted its holdings in shares of Aclaris Therapeutics by 125.3% during the fourth quarter. Rock Springs Capital Management LP now owns 6,204,309 shares of the biotechnology company's stock valued at $15,387,000 after purchasing an additional 3,450,814 shares during the last quarter. RA Capital Management L.P. purchased a new stake in shares of Aclaris Therapeutics during the fourth quarter valued at approximately $11,573,000. Finally, Millennium Management LLC grew its holdings in shares of Aclaris Therapeutics by 111.0% during the first quarter. Millennium Management LLC now owns 4,134,148 shares of the biotechnology company's stock valued at $6,325,000 after buying an additional 2,175,101 shares during the last quarter. 98.34% of the stock is currently owned by hedge funds and other institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.